Asthma in Children, Exercise, Rehabilitation
Conditions
Brief summary
Asthma, a prevalent chronic condition among children and adolescents, substantially impairs their quality of life. In addressing this significant health concern, this study focuses on the potential of a customized exercise rehabilitation program tailored for this young demographic. By employing a randomized controlled trial design, the research aims to divide participants into two distinct groups: one undergoing a personalized exercise regimen and the other receiving standard medical care. The 12-week intervention for the exercise group includes a combination of aerobic activities, strength training, and targeted breathing exercises. The study's primary aim is to rigorously evaluate the impact of this specialized exercise protocol on critical health aspects such as lung function, physical endurance, frequency of asthma attacks, and overall quality of life. The anticipated findings from this research are expected to shed new light on effective asthma management strategies and offer invaluable guidance for clinical practices dedicated to improving health outcomes in young asthma patients.
Interventions
BEHAVIORALPersonalized Exercise Rehabilitation
The experimental group will participate in a 12-week exercise intervention program, carefully transitioning from moderate-intensity interval training to high-intensity interval training. The progression of exercise intensity will be regularly adjusted based on each child's tolerance, ensuring a personalized approach to the regimen. The exercise program is structured into three phases: an adaptation phase, an intensification phase, and a consolidation phase. For each participant, the intensity of the exercises is calculated based on their reserve heart rate, allowing for a tailored and scientifically-grounded progression. This approach aims to optimize the exercise program's effectiveness while maintaining safety and adaptability to individual fitness levels and asthma conditions.
Sponsors
The Children's Hospital of Zhejiang University School of Medicine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
6 Years to 17 Years
Healthy volunteers
No
Inclusion criteria
1. Diagnosed with bronchial asthma; 2. No acute asthma attacks in the past three months; 3. Currently undergoing stable prophylactic treatment for asthma, with no changes in the treatment plan in the past three months.
Exclusion criteria
1. Suffering from other severe heart, lung, or musculoskeletal diseases; 2. Frequent acute asthma attacks or recent hospitalization records; 3. Changes in asthma medication treatment plan in the last three months; 4. Currently participating in other clinical trials that could affect the results of this study; 5. Any medical contraindications, such as severe exercise-induced asthma or other health issues affecting the ability to exercise; 6. Severe psychological or behavioral issues that may affect participation in training or adherence to the research protocol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Lung Function | up to 24 weeks | Forced Vital Capacity (FVC), Forced Expiratory Volume in One Second (FEV1), Forced Expiratory Flow 25% to 75% (FEF25-75), Peak Expiratory Flow (PEF) |
| Daily Physical Activity Level | up to 24 weeks | Daily Step Count (as measured by a pedometer), Energy Expenditure,Time Spent in Moderate-to-Vigorous Intensity Activity |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Body Composition | up to 24 weeks | Height, Weight, Body Fat, Skeletal Muscle Content |
| Sleep | up to 24 weeks | Number of Nighttime Awakenings, Sleep Duration |
| Asthma Control Status | up to 24 weeks | asthma control test(ACT) |
| Anxiety and Depression | up to 24 weeks | C-C-Ped-PROMIS |
| Inflammatory Mediators | up to 12 weeks | IL-4, IL-5, IL-13 |
| Health Related Quality of Life | up to 24 weeks | Asthma Quality of Life Questionnaire |
| Fractional Exhaled Nitric Oxide (FeNO) | up to 12 weeks | FeNO was determined by NIOX VERO |
Outcome results
None listed